Drug · DIN 02365952
ADVATE
BAXJ. II. 2 ML DILUENT. ANTIHEM. FACTOR (RECOMB.) PLASMA/ALBUMIN-FREE.
Authorized, but not sold for a year or more
Authorized, but the company reports it has not been sold in Canada for at least 12 months.
Status Dormant since July 22, 2021; first marketed March 5, 2012.
- Drug Identification Number (DIN)
- 02365952
- Company (DIN owner)
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Coagulation factor viii B02BD02
- Class
- Human
- Record last updated
- September 21, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ANTIHEMOPHILIC FACTOR (RECOMBINANT) | 500 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 27, 2021: NOC 25960New Drug Submission (NDS) · Transfer of drug identification number
- July 26, 2018: NOC 21141New Drug Submission (NDS) · Merger - buyout
- April 21, 2015: NOC 16815New Drug Submission (NDS) · Manufacturer name change
- March 18, 2011: NOC 12179Supplement to a New Drug Submission (SNDS) · Reconstitution in 2ml sterile water
Other DINs named ADVATE
- DIN 02284138 · Cancelled Post Market
- DIN 02284146 · Cancelled Post Market
- DIN 02284154 · Dormant
- DIN 02284162 · Dormant
- DIN 02313111 · Dormant
- DIN 02337193 · Dormant
- DIN 02365944 · Dormant
- DIN 02365979 · Approved
- DIN 02365987 · Approved
- DIN 02446405 · Approved
- DIN 02446413 · Approved
- DIN 02446421 · Approved
- DIN 02446448 · Approved
- DIN 02446456 · Approved
- DIN 02446464 · Approved
- DIN 02446472 · Approved
- DIN 02446480 · Approved